Exco InTouch Announces 1 Million Patients Supported Globally Through its Highly Scalable and Industry Leading Platform
Exco InTouch has announced that one million patients have now benefited from the company’s firmly established and industry leading platform. This significant number underlines the company’s established leadership position in the market and highlights the broad reach of Exco InTouch’s services.
The company’s platform is highly scalable with the proven capability to support cross-border programmes with large patient populations. As a consequence, at any one time hundreds of thousands of patients across multiple territories, time zones and languages benefit from Exco InTouch’s software and services. The geographic spread has so far encompassed patients in a multitude of clinical and healthcare programs across 70 different languages in 26,000 hospitals and clinics across the globe.
Comprehensive regulatory understanding and compliance underlies Exco InTouch’s growth and consistent track record of international success and is an essential attribute for managing clinical and health programs globally. The company is compliant to HIPAA, HITECH, Safe Harbor and international data protection and privacy regulations; thereby marking Exco InTouch out as the most compliant of all the digital patient engagement and data capture solutions providers.
Dale Jessop, Chief Technology Officer at Exco InTouch commented: “The capability to scale-up and to meet head on the challenge of modern clinical and health programmes is the key to success in the complex markets that we serve. To achieve this our platform has been developed to enable delivery of tailored digital and mobile solutions to large numbers of patients, each with different technological needs and expectations, across an array of different regions, languages and cultures.”
He added: “In the fast changing world of digital and mobile technology, the trick is to have the foresight and efficiency to rapidly evolve software and technology with the speed necessary to ensure that effective solutions, that actively engage patients and capture their data, are deployed seamlessly. Furthermore, sufficient investment is of critical importance to provide full confidence that resources are in place to sufficiently guarantee that platforms really are robust enough to meet the demands of servicing such large numbers of patients simultaneously, and on the global scale required, across all the multiple territories concerned.”
Tim Davis, CEO of Exco InTouch commented: “We are of course very pleased that our leading global expertise, knowledge, software and capabilities have been put to use in the servicing of clinical and healthcare programmes on such a scale, enabling the benefits of our advanced offering to be experienced by over a million patients. Indeed, we look forward to many more patients benefiting from our engaging solutions as we continue to expand and develop our advanced capabilities in the industry.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance